Sec Form 4 Filing - White William Richard @ Ventyx Biosciences, Inc. - 2023-01-23

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person White William Richard 2. Issuer Name and Ticker or Trading Symbol Ventyx Biosciences, Inc. [ VTYX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD, SUITE 250 3. Date of Earliest Transaction (MM/DD/YY) 01/23/2023 (Street) ENCINITAS, CA92024 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 01/23/2023 M 33,353 A $ 6.03 33,353 D Common Stock 01/23/2023 S( 1 ) 5,048 D $ 34.3258( 2 ) 28,305 D Common Stock 01/23/2023 S( 1 ) 21,278 D $ 35.0117( 3 ) 7,027 D Common Stock 01/23/2023 S( 1 ) 7,027 D $ 35.9095( 4 ) 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 6.03 01/23/2023 M 33,353 ( 5 ) 08/17/2031 Common Stock 33,353 $ 0 119,120 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other White William Richard C/O VENTYX BIOSCIENCES, INC. 662 ENCINITAS BLVD, SUITE 250 ENCINITAS, CA92024 X Signatures /s/ Christopher Krueger, as Attorney-in-Fact 01/24/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Shares were sold pursuant to a 10b5-1 trading plan adopted by the reporting person on September 22, 2022. ( 2 )The sales price reported is the weighted average sale price for 5,048 shares sold. These shares were sold in multiple transactions at prices ranging from $33.70 to $34.695 by the reporting person. Full information regarding the number of shares sold at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer. ( 3 )The sales price reported is the weighted average sale price for 21,278 shares sold. These shares were sold in multiple transactions at prices ranging from $34.705 to $35.7029 by the reporting person. Full information regarding the number of shares sold at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer. ( 4 )The sales price reported is the weighted average sale price for 7,027 shares sold. These shares were sold in multiple transactions at prices ranging from $35.7054 to $36.48 by the reporting person. Full information regarding the number of shares sold at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer. ( 5 )Option granted under pursuant to the Issuer's 2019 Equity Incentive Plan, as amended (the "2019 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2019 Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 22, 2021.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.